Skip to content
Menu

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.

Read at benzinga.com